Faculty

Back to Index
Mark Floyd Lew, MD
Professor of Clinical Neurology
Joseph P. Van Der Meulen, M.D. Chair in Parkinson's Disease Research in Honor of Robert J. Pasarow
Vice Chair, Department of Neurology
Division Chief, Movement Disorders
Neurology
HCC 3000 1520 San Pablo Street Health Sciences Campus Los Angeles
+1 323 442 5728

Overview

Dr. Lew has an international reputation for the treatment of patients with Parkinson’s disease, dystonia, and other movement disorders. He is a board certified neurologist and a fellow of the American Academy of Neurology. Dr. Lew is the director of the Division of Movement Disorders and serves as the vice chairman of the Department of Neurology. He has lectured extensively in the United States and abroad on clinical research related to new therapies for Parkinson’s disease and dystonia. Dr. Lew also collaborates closely with local and national advocacy organizations (e.g., the Hollyrod Foundation and the National Parkinson’s Foundation) to increase public awareness and to support research and care.

Publications

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Mov Disord. 2016 Sep; 31(9):1373-80. View in: PubMed

Lang AE, Rodriguez RL, Boyd JT, Chouinard S, Zadikoff C, Espay AJ, Slevin JT, Fernandez HH, Lew MF, Stein DA, Odin P, Fung VS, Klostermann F, Fasano A, Draganov PV, Schmulewitz N, Robieson WZ, Eaton S, Chatamra K, Benesh JA, Dubow J. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. Mov Disord. 2016 Apr; 31(4):538-46. View in: PubMed

Lew MF, Slevin JT, Krüger R, Martínez Castrillo JC, Chatamra K, Dubow JS, Robieson WZ, Benesh JA, Fung VS. Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism Relat Disord. 2015 Jul; 21(7):742-8. View in: PubMed

Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results. Mov Disord. 2015 Apr; 30(4):500-9. View in: PubMed

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93. View in: PubMed

Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug; 13(8):767-76. View in: PubMed

A randomized clinical trial of high-dosage coenzyme q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014 May 1; 71(5):543-52. View in: PubMed

Lew MF. Rasagiline treatment effects on parkinsonian tremor. Int J Neurosci. 2013 Dec; 123(12):859-65. View in: PubMed

Chinnapongse RB, Lew MF, Ferreira JJ, Gullo KL, Nemeth PR, Zhang Y. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol. 2012 Sep; 35(5):215-23. View in: PubMed

Feldman AL, Johansson AL, Gatz M, Flensburg M, Petzinger GM, Widner H, Lew MF, Pedersen NL, Wirdefeldt K. Accuracy and sensitivity of parkinsonian disorder diagnoses in two Swedish national health registers. Neuroepidemiology. 2012; 38(3):186-93. View in: PubMed

Lew MF, Somogyi M, McCague K, Welsh M. Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone: Effects on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off. Int J Neurosci. 2011 Nov; 121(11):605-13. View in: PubMed

Hauser RA, Reichmann H, Lew M, Asgharian A, Makumi C, Shulman KJ. Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease. Int J Neurosci. 2011 May; 121(5):246-53. View in: PubMed

Marvi MM, Lew MF. Polycythemia and chorea. Handb Clin Neurol. 2011; 100:271-6. View in: PubMed

Lew MF. The evidence for disease modification in Parkinson's disease. Int J Neurosci. 2011; 121 Suppl 2:18-26. View in: PubMed

Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23. View in: PubMed

Lew MF, Hauser RA, Hurtig HI, Ondo WG, Wojcieszek J, Goren T, Fitzer-Attas CJ. Long-term efficacy of rasagiline in early Parkinson's disease. Int J Neurosci. 2010 Jun; 120(6):404-8. View in: PubMed

Lew MF, Chinnapongse R, Zhang Y, Corliss M. RimabotulinumtoxinB effects on pain associated with cervical dystonia: results of placebo and comparator-controlled studies. Int J Neurosci. 2010 Apr; 120(4):298-300. View in: PubMed

Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, Sutton JP, Wolf JE. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol. 2010 Mar; 67(3):347-52. View in: PubMed

Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol. 2010 Jan-Feb; 33(1):5-10. View in: PubMed

Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 Mar 15; 24(4):564-73. View in: PubMed

Wirdefeldt K, Gatz M, Bakaysa SL, Fiske A, Flensburg M, Petzinger GM, Widner H, Lew MF, Welsh M, Pedersen NL. Complete ascertainment of Parkinson disease in the Swedish Twin Registry. Neurobiol Aging. 2008 Dec; 29(12):1765-73. View in: PubMed

McNicoll CF, Latourelle JC, MacDonald ME, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Saint-Hilaire MH, Massood T, Huskey KW, DeStefano AL, Gillis T, Mysore J, Goldwurm S, Pezzoli G, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord. 2008 Aug 15; 23(11):1596-601. View in: PubMed

DeStefano AL, Latourelle J, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts R, Guttman M, Racette BA, Perlmutter JS, Marlor L, Shill HA, Singer C, Goldwurm S, Pezzoli G, Saint-Hilaire MH, Hendricks AE, Gower A, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. Replication of association between ELAVL4 and Parkinson disease: the GenePD study. Hum Genet. 2008 Aug; 124(1):95-9. View in: PubMed

Molho E, Jankovic J, Lew M. Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008 May; 26 Suppl 1:43-53. View in: PubMed

Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH. The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med. 2008; 6:32. View in: PubMed

Lew M. Overview of Parkinson's disease. Pharmacotherapy. 2007 Dec; 27(12 Pt 2):155S-160S. View in: PubMed

Lew MF, Kricorian G. Results from a 2-year centralized tolcapone liver enzyme monitoring program. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):281-6. View in: PubMed

Lew MF, Pahwa R, Leehey M, Bertoni J, Kricorian G. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Curr Med Res Opin. 2007 Apr; 23(4):741-50. View in: PubMed

Hui JS, Lew MF. Calcification of the Basal Ganglia. Handb Clin Neurol. 2007; 84:479-86. View in: PubMed

Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, Golbe LI, Mark MH, Racette BA, Perlmutter JS, Parsian A, Guttman M, Nicholson G, Xu G, Wilk JB, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Suchowersky O, Labelle N, Growdon JH, Singer C, Watts RL, Goldwurm S, Pezzoli G, Baker KB, Pramstaller PP, Burn DJ, Chinnery PF, Sherman S, Vieregge P, Litvan I, Gillis T, MacDonald ME, Myers RH, Gusella JF. Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol. 2006 Jun; 63(6):826-32. View in: PubMed

Lew MF. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Expert Rev Neurother. 2005 Nov; 5(6):705-12. View in: PubMed

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91. View in: PubMed

Hui JS, Murdock GA, Chung JS, Lew MF. Behavioral changes as side effects of medication treatment for Parkinson's disease. Adv Neurol. 2005; 96:114-29. View in: PubMed

Lew MF. Duration of effectiveness of botulinum toxin type B in the treatment of cervical dystonia. Adv Neurol. 2004; 94:211-5. View in: PubMed

Lew MF. Review of the FDA-approved uses of botulinum toxins, including data suggesting efficacy in pain reduction. Clin J Pain. 2002 Nov-Dec; 18(6 Suppl):S142-6. View in: PubMed

Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct; 59(10):1541-50. View in: PubMed

DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet. 2002 May; 70(5):1089-95. View in: PubMed

Botulinum toxin type B: An effective treatment for alleviating pain associated with cervical dystonia. J Back Musculoskelet Rehabil. 2002 Jan 1; 16(1):3-9. View in: PubMed

Lew MF. Botulinum toxin type B (Myobloc, NeuroBloc): a new choice in cervical dystonia. Expert Rev Neurother. 2001 Nov; 1(2):143-52. View in: PubMed

Powered bySC CTSI